Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02530034 · ClinicalTrials.gov registry record · Phase 1
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Myelofibrosis, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 4
- Study locations
NCT02530034 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Myelofibrosis that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 72 participants, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02530034, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Myelofibrosis, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
Study Locations (4)
Georgia
- Augusta University - Augusta
New York
- Montefiore Medical Center, Albert Einstein College of Medicine - The Bronx
Texas
- M D Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02530034
The ClinicalTrials.gov registry entry for NCT02530034 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (92% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02530034 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02530034 about?
NCT02530034 is a clinical study titled "Hu8F4 in Treating Patients With Advanced Hematologic Malignancies". This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.
What is the current status of trial NCT02530034?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2019-01-31. Estimated completion is 2027-01-01.
What conditions does trial NCT02530034 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome.
What interventions are being tested in trial NCT02530034?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (DRUG).
Who is sponsoring clinical trial NCT02530034?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02530034 being conducted?
This trial has 4 study locations across Georgia, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.